Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBV virological control with two antiretroviral treatment-relief strategies in HIV-1/HBV coinfection
2023-508634-34-00Phase 2Authorised
- Sponsor
- Inserm
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatitis B (HBV) and Human immunodeficiency virus infection type 1 comparing Dolutegravir + lamivudine with Darunavir/ritonavir + lamivudine (2 arms). Primary endpoint: HBV virological failure at 96 weeks. Planned start May 2025; status: authorised.
02
Drugs
dolutegravirlamivudinedarunavirritonavir
03
Conditions
hepatitis B (HBV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2023-508634-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508634-34-00.